Targeting autophagy in doxorubicin-induced cardiotoxicity: A comprehensive review of scientific landscapes and therapeutic innovations
- 1 July 2025
- journal article
- review article
- Published by Elsevier in Ageing Research Reviews
- Vol. 110, 102818
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Sichuan Province (2024ZD0526000, 2023NSFSC1999, 2024NSFSC0534)
- National Natural Science Foundation of China (82372574, 82202793, 82172534)
- National Key Research and Development Program of China (2023YFC3603800, 2023YFC3603801)
This publication has 240 references indexed in Scilit:
- Follistatin‐like 1 protects against doxorubicin‐induced cardiotoxicity by preventing mitochondrial dysfunction through the SIRT6/Nrf2 signaling pathwayCell Biology International, 2024
- Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in ChildrenJAMA Network Open, 2024
- Scutellarin Attenuates Doxorubicin‐Induced Cardiotoxicity by Inhibiting Myocardial Fibrosis, Apoptosis and Autophagy in RatsChemistry & Biodiversity, 2022
- Autophagy at the intersection of aging, senescence, and cancerMolecular Oncology, 2022
- Exercise intervention decreases acute and late doxorubicin‐induced cardiotoxicityCancer Medicine, 2021
- Trehalose alleviates doxorubicin‐induced cardiotoxicity in female Swiss albino mice by suppression of oxidative stress and autophagyJournal of Biochemical and Molecular Toxicology, 2021
- Protective effect of valsartan against doxorubicin‐induced cardiotoxicity: Histopathology and metabolomics in vivo studyJournal of Biochemical and Molecular Toxicology, 2021
- Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With CancerJAMA, 2019
- The minipig as a new model for the evaluation of doxorubicin‐induced chronic toxicityJournal of Applied Toxicology, 2015
- Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisoloneCancer, 2005